Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 253-733-5 | CAS number: 37971-36-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Bayhibit AM (2-phosphonobutane-1,2,4-tricarboxylic acid) was tested for acute oral (gavage) toxicity in 10 rats by single applications that were well tolerated by all animals. The LD50 found was > 5 mL/kg bw (> 3250 mg/kg bw).
As there are no studies available for acute inhalation and acute dermal toxicity for 2-phosphonobutane-1,2,4-tricarboxylic acid a read-across approach with tetrasodium hydrogen 2-phosphonatobutane-1,2,4-tricarboxylate (Bayhibit AM-Tetra-sodium salt) is proposed.
In aqueous media, 2-phosphono-butane-1,2,4-tricarboxylic acid and tetrasodium hydrogen 2-phosphonatobutane-tricarboxylate dissociate into the corresponding anion (2-phosphonatobutane-tricarboxylate ion) and hydrogen ion (proton) and the sodium ion, respectively. The toxicological properties of 2-phosphonobutane-1,2,4-tricarboxylic acid and its tetrasodium salt are thought to be an effect of the phosphonato-carboxylate ion rather than of the sodium ion or the hydrogen ion (proton), which are normal constituents in body fluids and have no relevant toxic properties in low concentrations.
Therefore a read-across between 2-phosphono-butane-1,2,4-tricarboxylic acid and tetrasodium hydrogen 2-phosphonatobutane-tricarboxylate is justified.
Acute inhalation toxicity was determined for the test substance
tetrasodium hydrogen 2-phosphonatobutane-1,2,4-tricarboxylate. The LC50
(inhalation, rat) of tetrasodium hydrogen
2-phosphonatobutane-1,2,4-tricarboxylate is >1979 mg/m³.
A dose level of 1300 mg/kg of the test substance tetrasodium hydrogen
2-phosphonatobutane-1,2,4-tricarboxylate (32.6 % aqueous solution) was
examined for acute dermal toxicity resulting in a LD50 (dermal, rat) of
> 1300 mg/kg bw.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- NA
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: scientifically acceptable and sufficient documented
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- EU Method B.1 (Acute Toxicity (Oral))
- Deviations:
- yes
- Remarks:
- 10 rats were used instead of 3 rats.
- Principles of method if other than guideline:
- 10 rats were used instead of 3 rats.
- GLP compliance:
- not specified
- Test type:
- standard acute method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Weight at study initiation: 160-180 g.
- Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Doses:
- One time dosage of undiluted test substance in amount of 5 mL/kg
= 6500 mg/kg (calculation based on density = 1.3 kg/L)
A ca. 50 % solution of Bayhibit AM was used, therefore an amount of ca. 3250 mg/kg of active ingredient was applied. - No. of animals per sex per dose:
- 10
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Other examinations performed: clinical signs, body weight. - Statistics:
- NA
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- > 5 mL/kg bw
- Based on:
- dissolved
- Remarks:
- test substance
- Remarks on result:
- other: A ca. 50% aqueous solution of 2-phosphonobutane-1,2,4-tricarboxylic acid was used (density = 1.3 kg/l)
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- > 3 250 mg/kg bw
- Based on:
- act. ingr.
- Mortality:
- No mortality occurred during the study time.
- Clinical signs:
- other: No clinical signs were observed during the study time.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- LD50 > 5,0 mL/kg bw (equivalent to LD50 > 3250 mg/kg bw active ingredient)
- Executive summary:
2-Phosphonobutane-1,2,4-tricarboxylic acid was tested for acute oral toxicity in 10 male rats. A single dosage of 5 mL/kg bw (equivalent to about >3250 mg/kg bw) of active ingredient was administrated by gavage to 10 rats. During 14 days of observation, no mortality and no toxication symptoms were observed. The LD50 was therefore estimated to be > 3250 mg/kg bw (active ingredient (5 mL/kg bw of an aqueous 50% solution).
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 3 250 mg/kg bw
- Quality of whole database:
- Scientifically acceptable and sufficient documented.
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Not indicated
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: scientifically acceptable and well documented
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to other study
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 403 (Acute Inhalation Toxicity)
- Deviations:
- yes
- Remarks:
- Observation period of 7 days (instead of 14 days).
- Principles of method if other than guideline:
- Observation period of 7 days (instead of 14 days).
- GLP compliance:
- not specified
- Test type:
- traditional method
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- - Wistar-Albino
- Weight at study initiation: 160-180 g.
- Diet: Standard lab diet, ad libitum
- Water: ad libitum - Route of administration:
- inhalation: aerosol
- Type of inhalation exposure:
- whole body
- Vehicle:
- water
- Details on inhalation exposure:
- - System of generating particulates/aerosols: Spray (aerosol) generated by dynamic inhalation apparatus.
- Brief description of analytical method used: A piece of cotton wool was applied with the sprayed test substance (as was inhaled by the rats). The sprayed cotton was dried in an oven (water elution) and weighed by a gravimetric method that gave the weight of the dried substance that was applied. The figure was divided to give a determination of mg test substance in cubic meters (m3) of air. - Analytical verification of test atmosphere concentrations:
- yes
- Duration of exposure:
- 4 h
- Remarks on duration:
- no
- Concentrations:
- 800, 1479, 1979 mg/m³ air
- No. of animals per sex per dose:
- 5 rats
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 7 days
- Other examinations performed: clinical signs, haematological parameters - Statistics:
- No data.
- Preliminary study:
- A concentration of 1780 mg/m³ air, was applied for one hour to 10 male and female rats. No clinical symptoms were observed.
- Key result
- Sex:
- male/female
- Dose descriptor:
- LC0
- Effect level:
- 1 979 mg/m³ air (analytical)
- Exp. duration:
- 4 h
- Key result
- Sex:
- male/female
- Dose descriptor:
- LC50
- Effect level:
- > 1 979 mg/m³ air (analytical)
- Exp. duration:
- 4 h
- Mortality:
- No mortality during the time of the study.
- Clinical signs:
- other: No clinical symptoms appeared during the time of the study.
- Body weight:
- No data.
- Gross pathology:
- No data.
- Other findings:
- Haematological parameters: Erythrocytes, leucocytes, haemoglobin, haematocryte counts. No significant difference was found in the haematological results before and after the test substance application.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- Inhalation of the test substance in concentrations of less than / equal 1979 mg/m³ is harmless. No mortality occurred and no clinical and haematological effects were observed.
- Executive summary:
Acute inhalation toxicity was determined for the test substance, tetrasodium hydrogen 2-phosphonatobutane-1,2,4-tricarboxylate. Five male and female rats were exposed for 4 hours to the test substance in analysed concentrations of 800, 1479, 1979 mg/m³ air. After 7 days of observations, no mortality occurred, no clinical symptoms were observed and no significant difference was found in haematological parameters which were examined before and after exposure.
The LC50 can be estimated as >1979 mg/m³. 1979 mg/m³ was the highest concentration that could technically be achieved. Following the mentioned results, the tetrasodium hydrogen 2-phosphonatobutane-1,2,4-tricarboxylate is not to be classified as harmful via inhalation as at the highest achievable concentration (1979 mg/m³) no clinical symptoms were observed and no significant difference was found in haematological parameters which were examined before and after exposure.
- Endpoint:
- acute toxicity: inhalation
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- Not indicated
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: scientifically acceptable and well documented
- Justification for type of information:
- Please find the Justification attached to Chapter 13.2.
- Reason / purpose for cross-reference:
- read-across source
- Preliminary study:
- A concentration of 1780 mg/m³ air, was applied for one hour to 10 male and female rats. No clinical symptoms were observed.
- Key result
- Sex:
- male/female
- Dose descriptor:
- LC0
- Effect level:
- 1 979 mg/m³ air (analytical)
- Exp. duration:
- 4 h
- Key result
- Sex:
- male/female
- Dose descriptor:
- LC50
- Effect level:
- > 1 979 mg/m³ air (analytical)
- Exp. duration:
- 4 h
- Mortality:
- No mortality during the time of the study.
- Clinical signs:
- other: No clinical symptoms appeared during the time of the study.
- Body weight:
- No data.
- Gross pathology:
- No data.
- Other findings:
- Haematological parameters: Erythrocytes, leucocytes, haemoglobin, haematocryte counts. No significant difference was found in the haematological results before and after the test substance application.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- Inhalation of the test substance in concentrations of less than / equal 1979 mg/m³ is harmless. No mortality occurred and no clinical and haematological effects were observed.
- Executive summary:
Acute inhalation toxicity was determined for the test substance, tetrasodium hydrogen 2-phosphonatobutane-1,2,4-tricarboxylate. Five male and female rats were exposed for 4 hours to the test substance in analysed concentrations of 800, 1479, 1979 mg/m³ air. After 7 days of observations, no mortality occurred, no clinical symptoms were observed and no significant difference was found in haematological parameters which were examined before and after exposure.
The LC50 can be estimated as >1979 mg/m³. 1979 mg/m³ was the highest concentration that could technically be achieved. Following the mentioned results, the tetrasodium hydrogen 2-phosphonatobutane-1,2,4-tricarboxylate is not to be classified as harmful via inhalation as at the highest achievable concentration (1979 mg/m³) no clinical symptoms were observed and no significant difference was found in haematological parameters which were examined before and after exposure.
Referenceopen allclose all
No remarks.
No remarks.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LC50
- Value:
- 1 979 mg/m³ air
- Quality of whole database:
- Scientifically acceptable and well documented.
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 1 300 mg/kg bw
- Quality of whole database:
- Scientifically acceptable and well documented.
Additional information
In acute toxicity testing, Bayhibit AM (respectively Bayhibit AM-Tetra-sodium salt) revealed very low acute toxicity (oral, dermal and inhalation route):
Bayhibit AM was tested for acute oral toxicity in 10 male rats. A single dosage of 5 mL/kg bw (equivalent to about > 3250 mg/kg bw) of test substance was administrated by gavage to 10 rats. During 14 days of observation, no mortality and no toxication symptoms were observed. The LD50 was therefore >5 mL/kg bw equivalent > 3250 mg/kg bw (Löser, 1979). Due to the high dosage given in the study which resulted with no clinical effects and for animal welfare reasons, there seems to be no need in repeating the test of 1979.
In conclusion, the LD50 (oral, rat) of Bayhibit AM is >2000 mg/kg bw.
Following the mentioned results, the test substance is not to be classified as acute toxic (oral route).
Acute inhalation toxicity was determined for the test substance, PBTCNa4 (41.4 % aqueous solution) as aerosol generated by a dynamic inhalation apparatus. Five male and female rats were exposed for 4 hours to the test substance in analysed concentrations of 800, 1479, 1979 mg/m³ air.
After 7 days of observations, no mortality occurred, no clinical symptoms were observed and no significant difference was found in haematological parameters which were examined before and after exposure. The LC50 can be estimated as >1979 mg/m³ (Mihail F, Kimmerle G, 1976).
In conclusion, the LC50 (inhalation, rat) of PBTCNa4, applied as aerosol is >1979 mg/m³ (>1.979 mg/L).
Following the mentioned results, PBTCNa4 is not to be classified as harmful via inhalation as at the highest achievable concentration (1979 mg/m³) no clinical symptoms were observed and no significant difference was found in haematological parameters which were examined before and after exposure.
A 32.6 % aqueous solution (1300 mg/kg bw) of PBTCNa4 was examined for acute dermal toxicity. 5 male rats and 5 female rats were observed for 14 days after dermal application of the test substance. No mortality occurred during the study time. The LD50 (rat, oral) was therefore estimated as > 1300 mg/kg based on active ingredient of a 32.6 % aqueous solution of PBTCNa4.
No systemic clinical symptoms or local skin changes were observed. Minor changes were observed in body weight of female rats and no influence was observed in the growing development of the male rats. In a pathological examination of the rats at the end of the study, it was found that one male rat had a brighter (paler) liver with stains and another male rat had in addition a brighter kidney, two female rats, had also a brighter liver (Bomhard E, 1990).
In conclusion, the LD50 (dermal, rat) of PBTCNa4 is >1300 mg/kg bw.
Depending on the high water solubility and the very low log Pow (equivalent to a very low lipophilic character), 2-PBTCNa4 are not likely to penetrate the first skin barrier (stratum corneum). Thus, upon dermal contact, the bioavailability of PBTCNa4 are expected to be low. Additionally PBTCNa4 has an oral LD50 of ca. 8300 mg/kg bw. As no mortality occurred at a dermal dose of 1300 mg/kg bw PBTCNa4, it is assumed, that the effective LD 50 is much higher than this value, but in any case higher than 2000 mg/kg bw.
Following the mentioned results, the PBTCNa4 is not to be classified as acute toxic (dermal route).
Justification for classification or non-classification
In acute toxicity testing, 2-phosphonobutane-1,2,4-tricarboxylic acid revealed a low acute toxicity for the oral route and tetrasodium hydrogen 2-phosphonatobutane-1,2,4- tricarboxylate revealed a low acute toxicity for the dermal and inhalation route.
According to CLP classification criteria (Regulation (EC) No 1272/2008) a classification is not justified.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.